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I N T R O D U C T I O N
Outpatient and home parenteral antibiotic therapy (OHPAT)
for stable, immediately non-life-threatening infection is well
established in the USA and is considered to be a standard of
care [1]. In Europe, the degree to which OHPAT is practiced is
low (data from OHPATWorkshop, European Chemotherapy
Congress (ECC-2), 12 May, 1998, Hamburg) or con¢ned to
speci¢c centers in Europe [2^7]. It is assumed to be underuti-
lized, as there are few published data except from a small num-
ber of units [2^7]. However, there has long been a tradition of
OHPAT in the clinical oncology and hemotology setting and
this includes the delivery of chemotherapy and palliative care
[8]. Such services also exist for infections in patients with cys-
tic ¢brosis [9].This survey aimed to establish the views of Brit-
ish infection specialists (microbiologists and infectious disease
physicians) regarding the need for and provision of outpatient
or home-based programs for delivering parenteral antimicro-
bials, and to identify any possible barriers to their more wide-
spread use.
M A T E R I A L S A N D M E T H O D S
A postal survey of 345 infection specialists was carried out in
June 1999. Specialists were identi¢ed from a pharmaceutical
company marketing database. Questionnaires were sent with
an invitation to attend a home-care symposium and prepaid,
stamped addressed envelopes were provided. Respondents
were asked for their speciality (microbiologist or clinician)
and their experience with OHPAT in their current post, and
were asked to state the three most important perceived barriers
which may have prevented such a program. Participants were
also asked to list the three most appropriate infections which
could be managed with OHPAT, and ¢nally were given four
possible options for funding and clinical responsibility. Data
were recorded and analyzed using the epi-info statistical pack-
age.
R E S U L T S
There were 157 replies (response rate 46%), the majority of
which were from clinical microbiologists (145, 92%). Replies
were received from throughout theUK, with 70% from Eng-
land. The majority of respondents had experience of OHPAT
in either community-acquired (51%) or hospital-acquired
(62%) infection, but only 21% had an established program
within their institution. Of those without an established pro-
gram, 61% thought there was a de¢nite need and 14% did not
think there was a need for a formal program. Only 2%
thought intravenous therapy should always be administered in
hospital.
Barriers
Barriers to the development of an OHPAT program which
were identi¢edwere mainly organizational issues, particularly
source of funding, links between the hospital and community,
lack of leadership (or clinical apathy), lack of experience or
awareness of guidelines and identi¢cation and training of sta¡
and lack of time to organize a program. Another concern was
small numbers of patients or fragmentation of patient distri-
butionwithinTrusts. Concerns over patient safety and accept-
ability, particularly intravenous line care and administration
of antibiotics, were expressed by a few respondents (Table1).
Amenable infections
Deep-seated, soft tissue, device-related and complex respira-
tory tract infections were consistently identi¢ed as beingmost
appropriate for an OHPATprogram, but awide range of other
infections was also identi¢ed. Three per cent of respondents
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stated that any clinically stable infection which required pro-
tracted intravenous therapy could be considered for OHPAT
(Table 2).
Fiscal and clinical responsibility issues
There was no consensus regarding funding and clinical
responsibility for patients. Forty per cent thought that the
hospital should pay and specialists should take day-to-day
clinical responsibility. Fifty per cent thought that clinical care
should be shared between hospital and community practi-
tioners. Thirty-two per cent thought that funding should
come from the hospital budget, and 19% from the general
practitioners' budget.
D I S C U S S I O N
The survey was not intended to determine the true frequency
of OHPAT practice within the UK but to sample opinion
about OHPAT among infection specialists. The response rate
was suboptimal, but a range of experience and views was
expressed which may have wider relevance. Our ad hoc
experience from a series of meetings in the UK also con¢rms
this.This survey has shown that OHPAT is practiced through-
out the UK but that there are probably few `formal' programs
in place. Most specialists agree that intravenous antibiotic
therapy need not require hospitalization and that there is a
need for formalization of OHPAT programs. Safety issues
were infrequently thought to be a major barrier to the devel-
opment of a program, although organizational aspects were
thought to be of major importance.
There is broad consensus that deep-seated, non-life-threa-
tening infections are most suitable for OHPAT, although a
diverse group of infections was identi¢ed across speciality
boundaries. The cross-speciality nature of an OHPAT pro-
gram overcomes the concern expressed by many in this survey
of small numbers/sparsely distributed patients and highlights
the importance of ongoing input from referring specialists,
particularly regarding the surgical management of infection.
Experience inTayside has shown that such a program initiated
in one or two specialities (i.e. medicine and orthopedics) gains
momentum as other specialists become aware of the possibili-
ties and bene¢ts of outpatient therapy [10]. A separately
funded program ensures that the logistics of treatment can be
managed in a coordinated manner with clear lines of responsi-
bility and dedicated experienced personnel. This prevents
confusion over patient responsibility, which sometimes ensues
whenOHPATis administered on an ad hoc basis.
In Tayside, any infection is judged to be amenable to
OHPAT if patients are clinically stable, and require continua-
tion of parenteral antibiotics, and it is feasible to administer
the agent at home [10,14^16]. This can be extended to stable
infections which require intravenous therapy (perhaps for
only 48 h) but do not require hospitalization, e.g. some soft
tissue infections. A dedicated intravenous nurse practitioner
manages the logistics of care delivery and administers and
monitors treatment under the guidance of an infectious dis-
ease physician [10,11].The change in cost of treatment is prob-
Table 1 Perceived barriers to developing an OHPAT program and potential solutions
Perceived barriers to OHPAT in survey
No. (%) of
patients Potential solutions
Small number/fragmented distribution of patients 34 (27%) Coordinated Trust-wide service [10]
Funding issues 43 (35%) Requires dedicated funds and should be cost neutral
Lack of leadership 42 (34%) Identify an interested physician or microbiologist
Dif®culties in coordinating hospital and community care 37 (30%) Political will exists in UK. Dedicated nurse practitioner
works in both hospital and community [10]
Staf®ng/training issues 21 (17%) Appoint a dedicated nurse practitioner [10,11]
No time to organize 14 (11%) Argue case with managers over cost-effectiveness and get
dedicated time
Not safe (line care or drug administration) 12 (10%) OHPAT is as safe as hospital treatment [12]
Lack of guidelines/experience 17 (13%) European and USA guidelines exist [11,13]
More suitable options (oral, OHPAT on ad hoc basis). 8 (6%) Oral therapy may not be appropriate for some infections.
Ad hoc OHPAT puts unnecessary strain on nursing time in
hospital
Geographic constraints 6 (5%) Patients or community nurses/doctors could be involved
Not cost-effective 5 (4%) It is cost-effective
Patient expectations 4 (3%) Feasibility studies should be performed [14]
Up to three replies were given by each respondent.
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ably neutral, as the salary of this individual is o¡set by the
reduced cost of inpatient care. Although once-daily intrave-
nous antibiotics may be more expensive than multiply admi-
nistered antibiotics, hospital administration costs and nursing
time are signi¢cantly reduced. The obvious bene¢ts are felt
most by the patients, who can return to their homes and often
full-time employment while on treatment. Enhanced patient
satisfaction and quality of life has been demonstrated [10]. In
addition, ward sta¡ and community practitioners are not
given an additionalworkload in such a program.
Most Trusts in the UK do not have a dedicated infectious
disease physician to develop an OHPATprogram but all have
at least one microbiologist. It is possible that such a service can
be initiated by microbiologists with cooperation from inter-
ested clinicians. Clinical microbiologists are well placed to
have an overview of Trust-wide infection and generally have
unsolicited input into the management of most complex and
hospital-acquired infections, particularly with regard to
choice of antibiotic, route and duration of therapy. Guidelines
for patient selection and management have been published in
theUSA [13] andmore recently in Europe [11].The local orga-
nization of an OHPAT program can draw upon these guide-
lines but the ¢nance and sta¤ng must be structured around
local and regional healthcare priorities. In Tayside, OHPAT is
hospital led and funded although it is perceived that, with
time, experience and growing primary care awareness, GP
involvement will increase and a shared-care arrangement will
be developed. The perceived advantages and disadvantages of
OHPAT for hospitals and primary care are summarized in
Table 3. Clearly, due to the unique healthcare and ¢scal infra-
structures of European countries, interpretation of these data
will vary from country to country.
In the UK and elsewhere in Europe, there is a political will
to improve hospital-at-home services and to promote seamless
care between primary and secondary care providers [17].
Organizational and funding issues need to be addressed by
eachTrust or Regional Health Authority with such policies in
mind.
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Table 2 Infections which could be most appropriately treated with
intravenous antibiotics in a non-inpatient setting
Infections appropriate for OHPAT No. (%)
Bone and joint infections 106 (68%)
Skin and soft tissue infections 34 (22%)
Stable endocarditis 80 (51%)
Complicated lower respiratory tract infections 55 (35%)
Uncomplicated infections in hematology/oncology 23 (15%)
Intravascular device-related infections 20 (13%)
Infections with multiresistant organisms 15 (10%)
Uncomplicated meningococcal disease/other
meningitis in recovery phase
14 (9%)
Opportunistic infections related to HIV infection 8 (5%)
Intravascular graft- or prosthesis-related infection 8 (5%)
Deep-seated abscess 7 (4%)
Complicated urinary tract infection 8 (5%)
Any stable infection requiring prolonged
intravenous therapy
5 (3%)
Uncomplicated bacteremia 4 (3%)
Up to three conditions/scenarios were given by each respondent.
Table 3 Economic and related issues for the hospital and primary care when considering developing an OPHAT program
Hospital Primary care
Reduction in length of hospital stay () Prevention of hospitalization ()
Enhance patient quality of life () Enhance patient quality of life ()
Potential for bed number reduction (), i.e. bed closure Shared care and funding (e.g. Joint Investment Fund in
Scotland) ()
Potential reduction in waiting lists ()
Increase cost of consumables (e.g. vascular access
devices) or drugs (±)
Transfer of high-cost patient into community without
appropriate shift of funds (± ±)
Low demand (±) Increased GP workload (± ±)
Freeing up of beds will increase bed ef®ciency and consequently
cost (±)
Increased GP responsibility in uncertain therapeutic area (±)
Investment required to establish infrastructure (±) Greater role of community nursing team in delivering care ()
, potential opportunity or bene®t; ±, potential weakness or disadvantage.
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